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Summary
 
Apoptosis of peripheral blood T cells has been suggested to play an important role in the patho-
genesis of human immunodeficiency virus (HIV) infection. Spontaneous, Fas (CD95)–induced
and activation-induced T cell apoptosis have all been described in peripheral blood mononu-
clear cell cultures of HIV-infected individuals. We have previously shown that activation-
induced T cell apoptosis is Fas independent in peripheral blood T cells from HIV
 
1
 
 individuals.
In this study, we extend and confirm these observations by using an inhibitor of interleukin-1
 
b
 
converting enzyme (ICE) homologues. We show that z-VAD-fmk, a tripeptide inhibitor of
ICE homologues, can inhibit Fas-induced apoptosis of peripheral blood CD4
 
1
 
 and CD8
 
1
 
 T
cells from asymptomatic HIV
 
1
 
 individuals. z-VAD-fmk also inhibited activation (anti-CD3)–
induced CD4
 
1
 
 and CD8
 
1
 
 T cell apoptosis (AICD) in some but not all asymptomatic HIV
 
1
 
 in-
dividuals. Apoptosis was measured by multiparameter flow cytometry. The z-VAD-fmk inhib-
itor also enhanced survival of T cells in anti-Fas or anti-CD3 antibody-treated cultures and in-
hibited DNA fragmentation. AICD that could be inhibited by z-VAD-fmk was Fas independent
and could be inhibited with a blocking monoclonal antibody to tumor necrosis factor–related
apoptosis-inducing ligand (TRAIL), a recently described member of the TNF/nerve growth
factor ligand family. The above findings show that Fas-induced T cell apoptosis is ICE depen-
dent in HIV infection. AICD can be blocked by ICE inhibitors in some patients, and this
AICD is mediated by TRAIL. These results show that TRAIL can be a mediator of AICD in
T cells. These different mechanisms of peripheral blood T cell apoptosis may play different
roles in the pathogenesis of HIV infection.
 
S
 
everal studies have shown that spontaneous, Fas- and
activation-induced T cell apoptosis occurs in PBMCs
and purified T cells from HIV-infected individuals (1–5).
This apoptosis has been proposed as an important mecha-
nism in the pathogenesis of HIV disease involved in both
the functional defects and depletion of CD4
 
1
 
 T cells (6).
Previously, a number of investigators have shown that
activation-induced cell death in human T lymphocytes is
mediated by Fas–Fas ligand (FasL)
 
1
 
 interactions (7–10). Sig-
naling through Fas, a member of the TNF/nerve growth
factor (NGF) receptor superfamily (11), has been shown to
induce apoptosis of T cell clones and lines (12–14), to co-
stimulate proliferation and cytokine production of T cells
from healthy individuals (14), and to be involved in cyto-
toxic T lymphocyte–mediated killing (15, 16). We and
others have recently showed that peripheral blood CD4
 
1
 
and CD8
 
1
 
 T cells from HIV-infected individuals are espe-
cially susceptible to Fas-induced apoptosis and that this apo-
ptosis correlates with disease progression and severity (4, 5).
TNF-related apoptosis-inducing ligand (TRAIL)/Apo-
2L (17, 18) has been recently cloned and been shown to be
a member of the TNF/NGF family of ligands. Although
TRAIL, similar to Fas, has been shown to induce apoptosis
in a number of cell lines, it does not induce apoptosis in
 
1
 
Abbreviations used in this paper:
 
 AICD, activation-induced cell death; FasL,
Fas ligand; ICE, IL-1
 
b
 
 converting enzyme; NGF, nerve growth factor;
TRAIL, TNF-related apoptosis-inducing ligand.
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normal peripheral blood T and B cells. Thus, the biological
function of TRAIL has yet to be determined.
Our initial study on the role of Fas in T cell apoptosis of
HIV disease raised the question of whether Fas–FasL inter-
actions are involved in the activation-induced T cell apo-
ptosis observed in HIV infection. Using reagents that block
either Fas antigen or FasL, we recently showed that this ac-
tivation-induced T cell apoptosis is Fas/FasL independent
(19). In the present study, we confirm and extend these ob-
servations by using z-VAD-fmk, a tripeptide inhibitor of
interleukin-1
 
b
 
 converting enzyme (ICE) protease homo-
logues. We show that although Fas induced apoptosis of
peripheral blood T cells can be abrogated by z-VAD-fmk
in all asymptomatic HIV
 
1
 
 patients, activation-induced
CD4
 
1
 
 and CD8
 
1
 
 T cell apoptosis (AICD) of T cells can be
inhibited in some but not all patients. We report here that
TRAIL can mediate AICD of T cells. AICD of peripheral
blood T cells from HIV-infected individuals that could be
effectively inhibited by z-VAD-fmk could also be blocked
by a neutralizing monoclonal antibody to TRAIL, but not
to FasL. Our findings show that multiple mechanisms of T
cell apoptosis are operative in HIV infection and may play
different roles in the pathogenesis of HIV disease.
 
Materials and Methods
 
Samples and Materials.
 
Heparinized blood samples were ob-
tained after informed consent of asymptomatic HIV
 
1
 
 individuals.
Mouse monoclonal IgM antibody to Fas antigen (CD95) CH-11
(Immunotech, Westbrook, ME) was used for Fas-induced apo-
ptosis experiments. For AICD experiments, the anti-CD3 mono-
clonal antibody OKT3 was used. Blocking mouse monoclonal
antibody to FasL (NOK1; IgG1 isotype) was a gift by Dr. H.
Yagita (Juntendo University, Tokyo, Japan). For TRAIL block-
ing, the neutralizing monoclonal antibody M180 was used (IgG1
isotype; Immunex, Seattle, WA). The monoclonal anti-TNP an-
tibody 107.3 was used as an IgG1 isotype control (PharMingen,
San Diego, CA). ICE inhibitors were commercially purchased
Cbz–Val–Ala–Asp–fluoromethyl ketone (z-VAD-fmk; Enzyme
Systems Products, Dublin, CA), Cbz–Asp–Glu–Val–Asp–fluo-
romethyl ketone (z-DEVD-fmk; Enzyme Systems Products),
Cbz–Tyr–Val–Ala–Asp–chloromethyl ketone (z-YVAD-cmk;
Bachem, King of Prussia, PA), and Cbz–Phe–Ala–fluoro methyl
ketone (z-FA-fmk; Enzyme Systems Products). The IL-1
 
b
 
ELISA was a gift from Dr. J.S. Kenney (Syntex, Mountain View,
CA). RPMI-1640 (GIBCO BRL, Gaithersburg, MD) and FCS
(GIBCO BRL) contained 
 
,
 
0.03 EU/ml and 0.3 EU/ml, respec-
tively.
 
Anti-Fas and Anti-CD3–induced Apoptosis and Inhibition Experi-
ments.
 
PBMCs from asymptomatic HIV
 
1
 
 individuals were isolated
by density centrifugation on Ficoll–Hypaque. Freshly prepared
PBMCs were cultured for 24 h at 10
 
6
 
 cells/ml in RPMI-1640
plus 5% FCS in 24-well plates coated with or without monoclonal
anti-Fas antibody CH-11 or anti-CD3 antibody OKT3. Cultures
were performed at 37
 
8
 
C in a 5% CO
 
2
 
 humid atmosphere. Plates
were coated with 500 
 
m
 
l/well of 5 
 
m
 
g/ml of antibodies in PBS,
pH 7.4, for 2 h at 37
 
8
 
C. Plates were then briefly washed twice
with 500 
 
m
 
l/well RPMI-1640 plus 5% FCS and then washed one
more time as above for 30 min at 37
 
8
 
C. In the inhibition experi-
ments, PBMCs were preincubated with ICE inhibitors for 3 h at
37
 
8
 
C in a 5% CO
 
2
 
 humid atmosphere before being transferred to
antibody-coated plates. Apoptosis inhibition experiments using
the Jurkat T cell line were performed by preincubating with ICE
inhibitors for 3 h and then stimulating with 200 ng/ml CH-11 in
solution. The effect of the ICE inhibitors on IL-1
 
b
 
 production
was examined by preincubating PBMCs from HIV
 
2
 
 individuals
with inhibitors for 3 h, and then stimulating for 24 h with 1 
 
m
 
g/
ml LPS. Supernatants were then assayed in a specific IL-1
 
b
 
ELISA.
 
Apoptosis Measurement and DNA Fragmentation.
 
Apoptosis was
determined by staining cells with 1 
 
m
 
g/ml Hoechst 33342
(HO342; Molecular Probes, Eugene, OR) for 7 min on ice as
previously described (4). Cells were costained with anti-CD8–PE
(Becton Dickinson, Mountain View, CA), anti-CD4–FITC
(PharMingen), and anti-CD5–Cy5 (PharMingen) or anti-CD3–
Cy5 (PharMingen) for 15 min on ice. Anti-CD3–Cy5 was used
for staining in the anti-Fas–treated cultures, whereas anti-CD5–
Cy5 was used in the anti-CD3–treated cultures. After washes and
fixing in paraformaldehyde, 30,000 cells were analyzed by flow
cytometry using a Facstar
 
Ò
 
 (Becton Dickinson) and Desk software
(20). Apoptosis was determined by measuring HO342 staining
cells gated on forward and side scatter for lymphocytes. Absolute
numbers of live CD4
 
1
 
 and CD8
 
1
 
 T cell in culture were deter-
mined by measuring the percent of live nonapoptotic cells by
flow cytometry and counting the total number of PBMCs in cul-
ture (Coulter Counter model ZM; Coulter Corp., Hialeah, FL).
DNA fragmentation analysis was performed on PBMCs (2 
 
3
 
10
 
6
 
 cells) incubated with immobilized antibodies for 5 h. DNA
was extracted by centrifuging and then resuspending cells in 20 
 
m
 
l
of 50 mM Tris–HCl, pH 8.0, 10 mM EDTA, 0.5% sodium lauryl
sarcosylate, 0.5 mg/ml proteinase K, and incubating for 1 h at
50
 
8
 
C. RNAse at 100 
 
m
 
g/ml was then added and the extract was
further digested for 1 h at 50
 
8
 
C. DNA was run on a 2% agarose
gel in 45 mM Tris–borate, 1 mM EDTA, pH 8.0, stained with
0.5 
 
m
 
g/ml ethidium bromide, and visualized under UV light.
 
Statistical Analysis.
 
Data were analyzed by Wilcoxon’s signed-
rank test for paired data, Mann-Whitney U test, and analysis of
variance using JMP Statistics Guide (SAS Institute, Inc., Cary, NC).
 
Results
 
ICE Inhibitors and Anti-Fas–induced Apoptosis.
 
Preincu-
bation of cultures for 3 h with z-VAD-fmk tripeptide at 50
 
m
 
M inhibited 72% of anti-Fas–induced peripheral blood T
cell apoptosis in asymptomatic HIV-infected individuals
measured at 24 h by multiparameter flow cytometry (
 
n
 
 
 
5
 
 11;
Fig. 1 
 
A
 
). z-VAD-fmk (50 
 
m
 
M) inhibited 24-h Fas-induced
apoptosis of both CD4
 
1
 
 and CD8
 
1
 
 T cell (67 and 78%, re-
spectively; Fig. 1 
 
B
 
). z-VAD also increased the survival of
live cells in anti-Fas–treated cultures and inhibited DNA
fragmentation (Fig. 1, 
 
C
 
 and 
 
D
 
). At 10 
 
m
 
M, z-VAD-fmk
inhibited 32% of anti-Fas–induced apoptosis of CD3
 
1
 
 T
cells (data not shown). Spontaneous 24-h CD4
 
1
 
 and CD8
 
1
 
T cell apoptosis could not be inhibited by 50 
 
m
 
M z-VAD-
fmk. The control peptide z-FA-fmk (50 
 
m
 
M) had no effect
on either Fas-induced or spontaneous T cell apoptosis. The
z-YVAD-cmk and z-DEVD-fmk tetrapeptides at 50 
 
m
 
M
did not inhibit anti-Fas–induced T cell apoptosis of HIV
 
1
 
PBMCs (Fig 1, 
 
A–C
 
) and concentrations as high as 200
 
m
 
M still failed to inhibit apoptosis (data not shown).
Although anti-Fas–induced apoptosis of the Jurkat T cell
line could also be inhibited with z-VAD-fmk down to 
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concentrations of 10 
 
m
 
M (86% inhibition), higher concen-
trations of z-YVAD-cmk and z-DEVD-fmk were required
to inhibit this apoptosis (29 and 41% inhibition, respectively,
at 100 
 
m
 
M) (Fig. 2 
 
A
 
). Both z-VAD-fmk and z-YVAD-
cmk at 10 
 
m
 
M inhibited 77 and 73% of IL-1
 
b
 
 production
by LPS-stimulated PBMCs (Fig 2 
 
B
 
). z-FA-fmk had no ef-
fect on either Fas-induced apoptosis of the Jurkat T cell line
or on IL-1
 
b
 
 production by LPS-stimulated PBMCs.
 
ICE Inhibitors and Anti-CD3–induced Apoptosis.
 
Previ-
ously, we have shown that AICD of peripheral blood T
cells in HIV-infected individuals is Fas/FasL independent
(19). To extend these studies, we examined the effect of
the z-VAD-fmk tripeptide ICE inhibitor on anti-CD3–
induced 24-h AICD in HIV. CD5
 
1
 
 T cell apoptosis for
anti-CD3 alone, anti-CD3 plus z-VAD-fmk, and anti-
CD3 plus z-FA-fmk was 32.3 
 
6
 
 1.8, 22.9 
 
6
 
 1.9, and 29.7
 
6
 
 2.4%, respectively (
 
n
 
 
 
5
 
 25; Fig. 3 
 
A
 
); spontaneous
CD5
 
1
 
 T cell apoptosis was 14.1 
 
6
 
 1.8%. Inhibition of
AICD by z-VAD-fmk in asymptomatic HIV
 
1
 
 patients cor-
related with the level of AICD (
 
P
 
 
 
,
 
0.01; Spearman’s
Rho), with greater inhibition occurring in patients with
higher levels of AICD (Fig. 3 
 
B
 
). Inhibition of AICD by
z-VAD-fmk ranged from 0 to 87.2% (Fig. 3 
 
B
 
). In those
patients in which z-VAD-fmk inhibited AICD, both
CD4
 
1
 
 and CD81 T cell apoptosis was inhibited (data not
shown). When AICD was inhibited, z-VAD-fmk could in-
hibit DNA fragmentation and enhance survival of anti-
CD3 treatment cultures (data not shown). In all the above
experiments, the anti-FasL antibody failed to block both
ICE-dependent and independent AICD (Fig 4, A and B;
data not shown) confirming our previous findings with
HIV1 PBMCs (19). Addition of 100 U/ml of recombinant
IL-2 to these cultures also failed to inhibit 24-h AICD (data
not shown).
TRAIL Mediates ICE-dependent AICD in HIV-infected In-
dividuals. In patients with AICD that could be inhibited
Figure 1. Fas induced apoptosis of peripheral blood T cells from HIV1 individuals requires ICE-like activ-
ity. (A) z-VAD-fmk inhibits anti-Fas–induced CD31 T cell apoptosis in 24-h cultures as measured by multipa-
rameter flow cytometry. (a) Untreated culture, (b) anti-Fas antibody, (c) Anti-Fas–treated plus z-YVAD-fmk,
and (d) anti-Fas–treated plus z-VAD-fmk (e) anti-Fas–treated plus 2-FA-fmk. Percent apoptosis shown in upper
right corner. Representative experiment shown. (B) z-VAD-fmk inhibits anti-Fas–induced CD41 and CD81
T cell apoptosis. Pooled data from 11 individuals; four independent experiments performed (P ,0.01; Wil-
coxon’s signed-rank test for paired data; mean and standard errors shown). (C) z-VAD-fmk increases survival
of CD41 and CD81 T cells in anti-Fas antibody–treated cultures. Pooled data from seven individuals; three in-
dependent experiments performed (P ,0.05; Wilcoxon’s signed-rank test for paired data). (D) z-VAD-fmk
but not z-YVAD-cmk or z-DEVD-fmk inhibits DNA fragmentation induced by anti-Fas antibody in PBMCs
from HIV infected individuals. Representative experiment shown.1368 IL-1b Converting Enzyme Proteases and T Cell Apoptosis in HIV Infection
by z-VAD-fmk, all of CD51 T cell apoptosis could be in-
hibited by a neutralizing monoclonal antibody to TRAIL
(Fig. 4, A and B). Anti-CD3–induced 24-h apoptosis of
CD51 T cells was 15.9 6 2.7, 26.3 6 3.1, 14.1 6 1.8, 23.6 6
3.6, 25.9 6 3.1% for untreated, anti-CD3 antibody–treated,
anti-CD3 antibody plus anti-TRAIL–treated, anti-CD3
antibody plus anti-FasL–treated, and anti-CD3 antibody plus
isotype control–treated cultures, respectively. Anti-TRAIL
inhibited 24-h AICD in both CD41 and CD81 T cells.
Anti-TRAIL enhanced survival and inhibited DNA frag-
mentation in these anti-CD3–treated cultures (data not
shown). The blocking anti-FasL monoclonal antibody and
the isotype control antibody had no effect on T cell AICD
(Fig. 4, A and B). In patients in which z-VAD-fmk had lit-
tle or no effect on AICD (,15% inhibition) neither anti-
TRAIL nor anti-FasL antibody had any effect on T cell
AICD. However, the anti-FasL blocking antibody could
block anti-CD3–induced AICD of a T cell line generated
with PHA/IL-2 from a healthy HIV2 individual (Fig. 4 C).
Neither anti-TRAIL nor anti-FasL antibody had any effect
on spontaneous T cell apoptosis in HIV1 PBMC cultures
(data not shown).
Discussion
T cell apoptosis may play an important role in the patho-
genesis of HIV disease. We and others have previously
shown that peripheral blood T cells from HIV-infected in-
dividuals are especially susceptible to Fas-induced apoptosis
(4, 5). On the other hand, we have shown that activation-
induced peripheral blood T cell apoptosis (anti-CD3 stim-
ulation) in HIV1 individuals, is Fas independent (19). To
elucidate further T cell apoptosis in HIV infection in the
present study, we examined whether inhibiting ICE family
homologues can inhibit Fas- and activation-induced T cell
apoptosis.
Fas-induced apoptosis involves the activation of mem-
bers of both the ICE and CPP32 subfamilies of cysteine
proteases (21–23). The tripeptide z-VAD-fmk is an irre-
versible inhibitor of ICE protease and is expected to inhibit
other members of the ICE subfamily of cysteine proteases
(24). z-VAD-fmk can inhibit apoptosis induced by Fas
(25), overexpression of REAPER (26) and FLICE/MACH
(27), and a variety of other stimuli (28, 29). We found that
z-VAD-fmk inhibits Fas-induced peripheral blood CD41
and CD81 T cell apoptosis in asymptomatic HIV1 individ-
uals, thus showing that members of the ICE subfamily of
proteases are involved in this apoptosis. Tetrapeptide inhib-
itors of ICE (z-YVAD-cmk) or CPP32 (z-DEVD-fmk)
could not inhibit Fas-induced T cell apoptosis in PBMC
cultures. Previously, z-YVAD-cmk was shown to inhibit
Fas-induced apoptosis of purified CD41 and CD81 T cells
from HIV1 individuals with CD41 T cell apoptosis being
inhibited more efficiently than CD81 T cells (30). In our
study, the tripeptide z-VAD-fmk inhibitor was equally effi-
cient in inhibiting Fas-induced CD41 and CD81 T cell ap-
optosis. The lack of effect of tetrapeptides in our hands is
possibly due to differences in cellular uptake of these inhib-
Figure 2. Effect of ICE peptide inhibitors on (A) Fas induced 24-h ap-
optosis of the Jurkat T cell line and (B) IL-1b production by LPS-stimu-
lated PBMCs (24 h). Representative experiments shown.
Figure 3. Effect of z-VAD-fmk on AICD of
peripheral blood T cells from HIV1 patients.
Anti-CD3 antibody induced CD51 T cell apo-
ptosis (24 h) in the presence or absence of
z-VAD-fmk or control peptide z-FA-fmk
shown. (A) Inhibition of AICD by z-VAD-fmk
(n 5 25; horizontal bar depicts mean; P ,0.01
by Wilcoxon’s signed-rank test for paired data).
(B) Percent inhibition of AICD by z-VAD-fmk
correlates with the level of AICD (P ,0.01;
Spearman’s Rho).1369 Katsikis et al.
itors and this may explain why IL-1b production by
monocytes was inhibited by z-YVAD-fmk, whereas T cell
apoptosis was not.
In our studies, activation (anti-CD3)–induced CD41
and CD81 T cell apoptosis could be inhibited in some pa-
tients but not all, thus subdividing the HIV1 patients into
two groups with ICE-dependent and ICE-independent
AICD, respectively. Spontaneous T cell apoptosis could
not be inhibited by z-VAD-fmk. The ICE-dependent pe-
ripheral blood T cell AICD in HIV1 individuals was medi-
ated by TRAIL, as a blocking anti-TRAIL monoclonal an-
tibody inhibited this apoptosis. TRAIL, a member of the
TNF/NGF ligand family, has been shown to induce apo-
ptosis of transformed cell lines (17, 18) and TRAIL-induced
apoptosis requires ICE-like cysteine proteases (31). Our
findings show an involvement of TRAIL in AICD of pe-
ripheral blood T cells from HIV1 individuals. An involve-
ment of TRAIL in T cell AICD has not been previously
reported. Recently, cytotoxic activity in long-term cyto-
toxic assays has been demonstrated by T cells from per-
forin/FasL–deficient mice (32). Only a fraction of this per-
forin and FasL-independent cytotoxicity can be attributed
to TNF-a (32), suggesting that other members of the
TNF/NGF ligand family such as TRAIL may be involved
in long-term cytotoxicity. In our study, z-VAD-fmk and
anti-TRAIL inhibited T cell AICD in some patients, and
this inhibition correlated with the level of AICD, whereas
in other patients, they failed to significantly inhibit AICD.
Whether this reflects different stages of disease or levels of
peripheral blood T cell activation in these asymptomatic
patients is not known at the moment. Patients that exhib-
ited z-VAD-fmk–inhibitable/TRAIL–mediated T cell
AICD also had lower peripheral blood CD81 T cell abso-
lute counts (data not shown); although this was not statisti-
cally significant, it may indicate that CD81 T cell subsets
are involved in this apoptosis. CD81CD282 T cells in-
crease in peripheral blood of HIV1 patients when CD81 T
cells decrease (33, 34), raising the possibility that such ter-
minally differentiated cytotoxic T cells may be involved in
the TRAIL-mediated AICD we observed (35, 36). An-
other issue raised by our findings is whether there is in-
creased expression of TRAIL receptors during HIV infec-
tion. Recently, three TRAIL receptors have been cloned
(DR4, TR2, and TR3; references 37–39), two of which
can mediate apoptosis (37, 38). It will be important to de-
termine which one receptor or combination of receptors is
involved in AICD during HIV infection. Future studies
should address these questions.
In some HIV1 individuals, z-VAD-fmk had little or no
effect on AICD of peripheral blood T cells. It is not clear at
the moment whether this failure to inhibit AICD is due to
limitations in our experimental approach or whether this
AICD is truly ICE independent. If ICE independent, this
AICD may be mediated by other members of the ICE fam-
ily of cysteine proteases, such as members of the CPP32
subfamily that are not inactivated by z-VAD-fmk (25). Ap-
optosis of T cells that cannot be inhibited by z-VAD-fmk
but can be blocked by inhibitors of CPP32 have been pre-
viously reported (40). We have previously described a sim-
ilar ICE-independent T cell apoptosis in HIV-1 Tat pro-
tein–enhanced AICD (41). This raises the possibility that
the ICE-independent peripheral blood T cell AICD we
Figure 4. TRAIL, but not FasL, mediates z-VAD-fmk–inhibitable AICD of peripheral blood T cells from
HIV1 patients. (A) Blocking monoclonal antibody to TRAIL inhibits AICD in patients that display z-VAD-
fmk inhibitable AICD. Multiparameter flow cytometry shown of representative experiment. (a–d) Spontane-
ous apoptosis; (e–h) anti-CD3–induced apoptosis. (b and f) Anti-TRAIL antibody; (c and g) anti-FasL antibody;
(d and h) isotype control. Percent apoptosis is shown in upper right corner. Representative experiment is
shown. (B) Anti-TRAIL antibody inhibits AICD (n 5 7; mean and standard errors of pooled data shown; P ,0.05;
Wilcoxon’s signed-rank test for paired data). (C) Anti-FasL antibody inhibits anti-CD3–induced AICD of a
human T cell line generated from an HIV2 individual. Representative experiment of two performed shown.1370 IL-1b Converting Enzyme Proteases and T Cell Apoptosis in HIV Infection
found in HIV1 individuals may be due to Tat protein–
induced apoptosis (42). IL-2 withdrawal from the murine
CTLL cell line can also induce apoptosis, which cannot be
inhibited by z-VAD-fmk but is abrogated by CPP32 inhib-
itors (40, 43), thus raising the possibility that the ICE-inde-
pendent AICD in HIV1 PBMCs may be due to insufficient
IL-2 production in these cultures. However, this was
shown not to be the case, because recombinant IL-2 added
to these cultures failed to inhibit T cell apoptosis. Another
possible explanation for the ICE-independent AICD we
describe is that it may be due to a bystander killing induced
by cytotoxic CD81 T cells. Such cytotoxicity cannot be
inhibited by z-VAD-fmk, because granzyme B cannot be
directly inhibited by z-VAD-fmk and during the protease
activation cascade granzyme B circumvents the activation
of ICE by directly activating CPP32 and Mch3 (40, 44–
47). In our study, spontaneous T cell apoptosis of HIV1
PBMC cultures could not be inhibited by z-VAD-fmk;
whether this is the result of T cells having received the le-
thal hit in vivo or this apoptosis belonging to ICE-inde-
pendent AICD is not clear at the moment.
The present report extends and confirms our previous
studies (19) in which anti-CD3–induced AICD in HIV1
PBMCs was shown to be Fas independent. AICD of puri-
fied CD81 T cells in HIV infection has previously been
shown to be Fas independent, although purified CD41 T
cell AICD was shown to be Fas mediated (30). This appar-
ent discrepancy may be the result of using purified versus
mixed cell populations. We believe our studies using PBMCs
may be more relevant to what may be happening in vivo
since they address the interactions of different cellular sub-
sets. Purified CD41 or CD81 T cells may reflect a more ar-
tificial system, because T cells are restricted to interacting
exclusively to cells of the same subpopulation. On the
other hand, different modes of T cell stimulation may result
in different mechanisms of AICD; this has been reported
for superantigen-induced apoptosis, which has been shown
to require Fas–FasL interactions, whereas anti-CD3–induced
T cell death can proceed in the absence of Fas (48). In our
experiments, we chose to examine AICD induced by im-
mobilized anti-CD3 antibody, since this would reflect anti-
gen stimulation of T cells more closely. Recently, FasL up-
regulation on monocytes was shown to be deficient during
HIV infection (49). If also true for T cells, this FasL defi-
ciency may explain the paradox of having Fas/FasL-inde-
pendent T cell AICD in HIV1 individuals whose periph-
eral blood T cells are sensitive to Fas killing.
Our findings show that in HIV1 individuals Fas-induced
apoptosis of peripheral blood CD41 and CD81 T cells re-
quires the activation of cysteine proteases of the ICE sub-
family. Activation-induced T cell apoptosis in some patients
could be inhibited by z-VAD-fmk. This AICD in HIV1
individuals was mediated by TRAIL, showing a role for
TRAIL in T cell AICD. Our findings indicate that multi-
ple mechanisms of T cell apoptosis are operative in HIV in-
fection and, thus, possibly contributing differently to disease
pathogenesis.
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